Expensify Inc vs Nuwellis Inc — how do they compare? Expensify Inc trades at $2.28 (market cap $209.73M), while Nuwellis Inc trades at $1.51 (market cap $542.80K). The key difference: Expensify Inc is far larger — about 386.4× Nuwellis Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| EXFY | NUWE | |
|---|---|---|
Market Cap | $209.73M | $542.80K |
Sector | Technology | Technology |
52-Week High | $2.69 | $220.50 |
52-Week Low | $0.75 | $1.42 |
Enterprise Value | $149.35M | -$1.27M |
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.4, down 2.83% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $33.9 million, beating EPS estimates, and raised free cash flow guidance. However, it remains unprofitable on a net income basis, with a negative margin of -11.31% and a high P/E ratio of 258.82, indicating a premium valuation despite losses. Recent news highlights expansion into Europe and AI product enhancements.
The outlook is mixed; operational improvements and AI-driven growth offer upside, but persistent losses and high valuation pose risks. Analyst sentiment is balanced with a 44% buy rating. Investors should weigh the potential for margin expansion against the challenge of achieving sustained profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →